Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial-Reference-Cited by-同舟云学术

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Published:2014-05-22 Issue:21 Volume:123 Page:3247-3254
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Stilgenbauer Stephan¹,Schnaiter Andrea¹,Paschka Peter¹,Zenz Thorsten¹²,Rossi Marianna³,Döhner Konstanze¹,Bühler Andreas¹,Böttcher Sebastian⁴,Ritgen Matthias⁴,Kneba Michael⁴,Winkler Dirk¹,Tausch Eugen¹,Hoth Patrick¹,Edelmann Jennifer¹,Mertens Daniel¹⁵,Bullinger Lars¹,Bergmann Manuela¹,Kless Sabrina¹,Mack Silja¹,Jäger Ulrich⁶,Patten Nancy⁷,Wu Lin⁷,Wenger Michael K.⁸,Fingerle-Rowson Günter⁸⁹,Lichter Peter¹⁰,Cazzola Mario³,Wendtner Clemens M.⁹¹¹,Fink Anna M.⁹,Fischer Kirsten⁹,Busch Raymonde¹²,Hallek Michael⁹,Döhner Hartmut¹

Affiliation:

1. Department of Internal Medicine III, Ulm University, Ulm, Germany;

2. Department of Translational Oncology, National Center for Tumor Diseases and German Cancer Research Center, and Department of Medicine V, University of Heidelberg, Heidelberg, Germany;

3. Department of Hematology Oncology, Fondazione Istituto Di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, University of Pavia, Italy;

4. Second Department of Medicine, University Hospital of Schleswig-Holstein, Campus Kiel, Kiel, Germany;

5. Cooperation Unit “Mechanisms of Leukemogenesis,” German Cancer Research Center, Heidelberg, Germany;

6. Department of Hematology, Medical University of Vienna, Vienna, Austria;

7. Roche Molecular Systems, Pleasanton, CA;

8. Pharmaceuticals Division, F. Hoffmann-La Roche Ltd., Basel, Switzerland;

9. Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany;

10. Division of Molecular Genetics, German Cancer Research Center, Heidelberg, Germany;

11. Department I of Internal Medicine, Klinikum Schwabing, Munich, Germany; and

12. Institute for Medical Statistics and Epidemiology, Technical University Munich, Munich, Germany

Abstract

Key Points Independent prognostic impact of biological markers, notably TP53 and SF3B1 mutations, in CLL patients requiring therapy. NOTCH1 mutation as a predictive factor for reduced benefit from the addition of rituximab to FC chemotherapy.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/21/3247/1377483/3247.pdf

Reference31 articles.

1. Chronic lymphocytic leukemia.;Chiorazzi;N Engl J Med,2005

2. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.;Hallek;Blood,2008

3. Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience.;Abrisqueta;Blood,2009

4. From pathogenesis to treatment of chronic lymphocytic leukaemia.;Zenz;Nat Rev Cancer,2010

5. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.;Damle;Blood,1999

Cited by 417 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transforming CLL management with immunotherapy: Investigating the potential of CAR T-cells and bispecific antibodies;Seminars in Hematology;2024-01

2. Predictive and prognostic molecular biomarkers in lymphomas;Pathology;2023-12

3. Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax;Clinical Cancer Research;2023-11-13

4. Efficacy and safety outcomes of single-agent ibrutinib therapy in chronic lymphocytic leukemia and relapsed/refractory mantle-cell lymphoma;The European Research Journal;2023-11-04

5. Aging and Age-Related Epigenetic Drift in the Pathogenesis of Leukemia and Lymphomas: New Therapeutic Targets;Cells;2023-09-30